VREX — Varex Imaging Corporation

Varex Imaging Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $210 million, up 5% year-over-year, towards the high end of guidance.
• Non-GAAP Gross Margin: 34%, at the high end of expectations.
• Non-GAAP EBITDA: $29 million, up 12% year-over-year.
• Non-GAAP EPS: $0.19, an increase from $0.10 in the previous year.
• Medical Segment Revenue: $145 million (flat year-over-year).
• Industrial Segment Revenue: $65 million, up 17% year-over-year.
• Operating Income: $19 million, with an operating margin of 9%, improved from 7% in Q1 2025.
• Cash Position: $126 million, down $30 million from Q4 2025; net cash outflow from operations was $16 million primarily due to inventory increase.

2. Strategic Updates and Business Highlights

• Medical Segment: Stable performance with strong demand for CT and digital detectors. Engagement with customers around next-generation system designs is increasing.
• Industrial Segment: Significant growth driven by cargo security systems and nondestructive testing applications. The company is focusing on real-time manufacturing solutions.
• RSNA Conference: Positive reception for new technologies, with over 150 customer meetings focused on design win opportunities. The company is adopting a modality-based approach to enhance customer engagement.
• India Operations: The factory for detectors is operational, and a new tube factory is under construction, expected to enhance local supply and reduce costs.

3. Forward Guidance and Outlook

• Q2 Guidance: Expected revenue between $210 million and $225 million; non-GAAP EPS projected between $0.15 and $0.25.
• Long-term Outlook: Positive customer engagement and pipeline development suggest potential for sustained growth, particularly in the Industrial segment. The company is optimistic about converting design opportunities into revenue in fiscal 2026 and beyond.

4. Bad News, Challenges, or Points of Concern

• Inventory Increase: Inventory rose by $29 million, attributed to preparations for anticipated demand and ongoing qualification cycles in India. This increase is seen as a burden on the P&L in the short term.
• China Market Stability: While China contributes 17% of revenue, the outlook remains flattish to slight growth due to macroeconomic uncertainties.
• Gross Margin Pressure: Margins in the Medical segment are challenged, particularly in radiography, and the company is working to improve competitiveness through production in India.

5. Notable Q&A Insights

• Customer Sentiment: CEO Sunny Sanyal expressed optimism about customer engagement and order activity in both Medical and Industrial segments, indicating a shift from maintenance-focused discussions to new product development.
• India Operations: The India factory is resonating well with customers, who prefer local content. However, the ramp-up in operations is currently a financial burden.
• Photon Counting Technology: Progress is being made with two OEMs engaged in product commercialization, with a focus on democratizing technology for broader market access.
• Debt Refinancing Plans: The company plans to refinance its high-yield debt before October 2026, currently at a 7.875% interest rate, with hopes to lower it through refinancing efforts.

Overall, Varex Imaging reported a solid start to fiscal 2026, with growth in the Industrial segment and stable performance in Medical, while navigating challenges related to inventory and market conditions in China.